Immune checkpoint therapy (ICT) can provide durable clinical responses and improve
overall survival. However, only subsets of patients with specific tumor types respond to ICT …

Immune checkpoint inhibitors (ICIs) have made an indelible mark in the field of cancer
immunotherapy. Starting with the approval of anti-cytotoxic T lymphocyte-associated protein …

Background The responses of cancer patients to immune checkpoint inhibitors (ICIs) vary in
success. CD8+ tumor infiltrating lymphocytes (TILs) play a key role in killing tumor cells. This …

Cancer growth and progression are associated with immune suppression. Cancer cells
have the ability to activate different immune checkpoint pathways that harbor …

Recent breakthroughs in tumor immunotherapy such as immune checkpoint blockade (ICB)
antibodies, have demonstrated the capacity of the immune system to fight cancer in a …

Advances in cancer immunity have promoted a major breakthrough in the field of cancer
therapy. This is mainly associated with the successful development of immune checkpoint …

Background Tumor infiltrating lymphocytes (TILs) reflect adaptive antitumor immune
responses in cancer and are generally associated with favorable prognosis. However, the …

The immune landscape of a tumor is highly connected to patient prognosis and response to
treatment, but little is known about how natural killer (NK) cells predict overall survival (OS) …

Tumor-infiltrating lymphocytes (TILs) are associated with prognosis in various tumors.
However, it remains controversial whether the presence of TILs is related to an improved …

Although the clinical development of immune checkpoint inhibitors (ICIs) therapy has
ushered in a new era of anti-tumor therapy, with sustained responses and significant …